Can lamotrigine cause suicidal ideation?

Can Lamotrigine Cause Suicidal Ideation?

Yes, lamotrigine can cause suicidal ideation, though the evidence is mixed and the absolute risk appears relatively low. The most concerning data comes from a 2010 nationwide Danish study showing lamotrigine was associated with a significantly increased risk of suicide shortly after treatment initiation (OR: 3.15,95% CI: 1.35-7.34) 1. However, this finding is contradicted by other evidence suggesting lamotrigine may actually have protective effects in certain populations.

Understanding the Contradictory Evidence

Evidence Supporting Increased Risk

The strongest evidence for concern comes from large-scale pharmacoepidemiologic studies:

• Danish nationwide study (2010): Found lamotrigine associated with a 3-fold increased suicide risk shortly after treatment initiation, particularly in the first weeks to months 1

• US cohort study (2010): Demonstrated increased risk of suicidal acts with lamotrigine compared to topiramate (HR: 1.84,95% CI: 1.43-2.37) 2

• Case reports: Document severe akathisia, anxiety, and suicidal ideation when lamotrigine is combined with aripiprazole and antidepressants, suggesting drug interaction risks 3

Evidence Suggesting Protective Effects

Conversely, other research indicates potential antisuicidal properties:

• Bipolar disorder cohort (2005): Showed numerically lower relative risk of suicidal ideation with lamotrigine compared to lithium, valproate, and carbamazepine, though not statistically significant 4

• Prospective observational study (2015): In 969 bipolar patients, suicide risk decreased from 17% at baseline to 2.1% after 6 months of lamotrigine treatment, with no suicide attempts or completed suicides during the study 5

• Case report (2026): Documented sustained antisuicidal effect in treatment-resistant depression when lamotrigine was used as augmentation 6

Clinical Risk Assessment Algorithm

Highest Risk Period: First 1-3 months after initiation or dose escalation

Risk Factors to Assess:

• Age <25 years (FDA boxed warning applies through age 24)
• Concurrent use of aripiprazole or other antipsychotics
• History of previous suicide attempts
• Comorbid mood or anxiety disorders
• Recent treatment initiation or dose increase

Practical Management Recommendations

Monitoring Protocol

1. Baseline assessment: Document current suicidal ideation, psychiatric history, and concurrent medications before starting lamotrigine

2. Intensive early monitoring:

   • Weekly contact (phone or in-person) for first month
   • Biweekly for months 2-3
   • Monthly thereafter if stable

3. Specific warning signs to monitor:

   • New or worsening suicidal thoughts
   • Severe akathisia or restlessness
   • Behavioral activation/agitation
   • Increased anxiety or insomnia

When to Discontinue

Immediately stop lamotrigine if:

• New suicidal ideation emerges
• Existing suicidal thoughts worsen significantly
• Severe akathisia develops (especially with concurrent aripiprazole)
• Patient reports intolerable anxiety or agitation

Drug Interaction Caution

The combination of lamotrigine with aripiprazole and antidepressants appears particularly problematic, with case reports showing severe akathisia and suicidal ideation 3. If this combination is necessary, start with the lowest possible doses and monitor extremely closely.

Context-Specific Considerations

For bipolar disorder: The evidence is most favorable in this population, with some studies suggesting protective effects after the initial high-risk period 5, 4

For epilepsy: The 2023 FAERS database analysis found lamotrigine had significantly lower odds of suicidality compared to older antiseizure medications (aOR: not specifically reported for lamotrigine alone, but grouped with older ASMs) 7

For treatment-resistant depression: Limited evidence suggests potential benefit, but this is off-label use requiring careful monitoring 6

Common Pitfalls to Avoid

1. Assuming all antiepileptic drugs carry equal risk: The evidence shows marked variability between different agents 1, 7

2. Inadequate early monitoring: The highest risk period is the first 1-3 months; this is when vigilance must be greatest

3. Ignoring drug interactions: The combination with aripiprazole appears particularly problematic 3

4. Failing to educate patients and families: They must know to report new or worsening suicidal thoughts immediately

Bottom Line for Clinical Practice

While lamotrigine carries an FDA boxed warning for suicidal thinking and behavior through age 24 (consistent with all antiepileptic drugs), the actual risk appears variable and context-dependent. The critical action is intensive monitoring during the first 3 months of treatment, with immediate discontinuation if suicidal ideation emerges or worsens. The drug should be avoided in patients with recent suicide attempts or active suicidal ideation unless the potential benefits clearly outweigh risks and close monitoring is feasible.